Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-565.61M |
| Operating Margin | 0.00% |
| Return on Equity | -80.10% |
| Return on Assets | -46.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.56 |
| Price-to-Book | 9.70 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -14.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $206.55M |
| Float | $91.79M |
| % Insiders | 56.02% |
| % Institutions | 54.65% |
Volatility is currently contracting
LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law.
Immunovant stock fell roughly 6% to a more-than-three-month low on September 23, 2026 after the IMVT-1402 cutaneous lupus study missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IMVT investors who lost money.
Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies All other clinical development timelines remain on track DURHAM, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant NASDAQ: IMVT.
IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.
All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren's disease (SjD) and cutaneous lupus erythematosus (CLE) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C.
I initiate coverage of Immunovant with a BUY rating and a $50 price target, driven by optimism around IMVT-1402's differentiated profile. IMVT-1402 demonstrates strong IgG reduction with minimal albumin and LDL impact, potentially best-in-class, with Graves' disease as the principal valuation driver. My valuation assumes ~$4B probability-adjusted peak sales and a conservative 2.5x sales multiple, supporting a ~$10.9B equity value, or $50 per share.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IMVT and any ticker you trade — then tracks every position and per-strategy win rate.
